Company Filing History:
4 out of 2,405 
2 out of 4,770 
1 out of 35 
Years Active: 2008-2019
Title: Innovations of Shane W Krska
Introduction
Shane W Krska is a notable inventor based in New Providence, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target neurological and psychiatric disorders. With a total of four patents to his name, Krska's work is focused on improving treatments for conditions such as Alzheimer's disease and other cognitive impairments.
Latest Patents
Krska's latest patents include a process for making M1 receptor positive allosteric modulators. This invention provides novel processes for the preparation of compounds such as 3-[(1S,2S)-2-hydroxycyclohexyl]-6-[(6-methylpyridin-3-yl)methyl]benzo[h]-quinazolin-4(3H)-one, salts, and derivatives thereof. The compounds synthesized by these processes are useful for treating Alzheimer's disease and other diseases mediated by the muscarinic M1 receptor. Another significant patent is for the preparation of an orexin receptor antagonist. This invention is directed to processes for preparing a diazepane compound that acts as an antagonist of orexin receptors, which is useful in the treatment or prevention of neurological and psychiatric disorders.
Career Highlights
Throughout his career, Krska has worked with prominent companies in the pharmaceutical industry, including Merck Sharp & Dohme Corporation and Merck & Company, Inc. His experience in these organizations has contributed to his expertise in drug development and innovation.
Collaborations
Krska has collaborated with several professionals in his field, including Yi Xiao and Joseph D Armstrong, III. These collaborations have likely enhanced his research and development efforts, leading to the successful patents he holds today.
Conclusion
Shane W Krska is a distinguished inventor whose work has the potential to significantly impact the treatment of various neurological and psychiatric disorders. His innovative patents reflect his commitment to advancing pharmaceutical science and improving patient outcomes.